Riham F. George
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Riham F. George has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Hanan H. Georgey
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
8 shared publicationsGhaneya S. Hassan
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt; Pharmaceutical Chemistry Department, School of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt
4 shared publications- Hamdy M. Abdel-Rahman
Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
4 shared publications - Abdalla R. Mohamed
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt
3 shared publications - Claudiu Trandafir Supuran
Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, Sesto Fiorentino, Firenze, 50019, Italy
3 shared publications - Hanan H. Georgey
Department of Pharmaceutical Chemistry, Faculty of Pharmacy Cairo University Cairo Egypt
3 shared publications
Latest Publications
- Open Access
- 16 February 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (11) , 9590-9607
Pyrazolo[3,4- d ]pyrimidine derivatives as VEGFR-2 and EGFR T790M dual inhibitors: design, docking, ADMET, synthesis and anticancer evaluations
Novel pyrazolo[3,4- d ]pyrimidine derivatives have been designed, synthesized and examined as inhibitors of both EGFR T790M and VEGFR-2.
- 16 February 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (11) , 9590-9607
Open AccessPyrazolo[3,4- d ]pyrimidine derivatives as VEGFR-2 and EGFR T790M dual inhibitors: design, docking, ADMET, synthesis and anticancer evaluations
Novel pyrazolo[3,4- d ]pyrimidine derivatives have been designed, synthesized and examined as inhibitors of both EGFR T790M and VEGFR-2.
- 15 September 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (19) , 2345-2360
Design and synthesis of novel 3,5-diphenyl pyrazolines acting as potent EGFR inhibitors with off-target antileukemic effect
Searching for novel epidermal growth factor receptor (EGFR) inhibitors, 1-substituted 3,5-diphenyl pyrazolines 4a-i, 5a-i, 6a, and 6b bearing the terminal piperidine or morpholine moieties commonly observed in clinically approved EGFR inhibitors were synthesized as novel anti-cancer agents acting via EGFR inhibition. A series of 3,5-diphenyl pyrazolines was synthesized and screened for in vitro anti-cancer activity against 60 NCI cell lines. Pyrazolines 5d and 6a revealed broad-spectrum cytotoxic activities and potent EGFR inhibition with IC50 values of 2.30 µM and 1.47 µM, respectively, in comparison to Vandetanib (IC50 = 0.5 µM) and Gefitinib (IC50 = 0.04 µM). Interestingly, compound 6a demonstrated a promising cytotoxic activity against the leukemia cell line (HL-60) and safety toward the normal cell line HSF. Additionally, compound 6a up-regulated proapoptotic markers and down-regulated Bcl-2 as an antiapoptotic marker in HL-60 cells. Docking simulations explained the EGFR inhibitory actions of 5d and 6a compared to Gefitinib. According to predictive models of oral bioavailability and drug-likeness, pyrazolines 5d and 6a are expected to be bioavailable and drug-like compounds. Pyrazolines 5d and 6a are novel EGFR inhibitors with a broad-spectrum anti-cancer activity, and 6a has off-target antileukemic effect.
- 15 September 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (19) , 2345-2360
Design and synthesis of novel 3,5-diphenyl pyrazolines acting as potent EGFR inhibitors with off-target antileukemic effect
Searching for novel epidermal growth factor receptor (EGFR) inhibitors, 1-substituted 3,5-diphenyl pyrazolines 4a-i, 5a-i, 6a, and 6b bearing the terminal piperidine or morpholine moieties commonly observed in clinically approved EGFR inhibitors were synthesized as novel anti-cancer agents acting via EGFR inhibition. A series of 3,5-diphenyl pyrazolines was synthesized and screened for in vitro anti-cancer activity against 60 NCI cell lines. Pyrazolines 5d and 6a revealed broad-spectrum cytotoxic activities and potent EGFR inhibition with IC50 values of 2.30 µM and 1.47 µM, respectively, in comparison to Vandetanib (IC50 = 0.5 µM) and Gefitinib (IC50 = 0.04 µM). Interestingly, compound 6a demonstrated a promising cytotoxic activity against the leukemia cell line (HL-60) and safety toward the normal cell line HSF. Additionally, compound 6a up-regulated proapoptotic markers and down-regulated Bcl-2 as an antiapoptotic marker in HL-60 cells. Docking simulations explained the EGFR inhibitory actions of 5d and 6a compared to Gefitinib. According to predictive models of oral bioavailability and drug-likeness, pyrazolines 5d and 6a are expected to be bioavailable and drug-like compounds. Pyrazolines 5d and 6a are novel EGFR inhibitors with a broad-spectrum anti-cancer activity, and 6a has off-target antileukemic effect.
- 13 March 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (6) , 725-745
3,5-Disubstituted pyrazoline as a promising core for anticancer agents: mechanisms of action and therapeutic potentials
The rapidly growing interest in the literature about the anticancer activity of 3,5-disubstituted pyrazolines and their promising therapeutic potentials/pharmacological properties, supported by the number of pyrazoline derivatives currently in clinical use or clinical trials, encouraged us to review the in vitro antiproliferative effects and biochemical investigations of probable mechanisms of action. Nevertheless, many reported pyrazoline-bearing compounds have anticancer activity without an explored mode of action, which opens new research avenues to examine their biochemical profiles further. Therefore, 3,5-disubstituted pyrazoline is a promising core that can be used to design new derivatives with anticancer activity based on the structure-activity relationship summarized in this review to obtain higher potency and selectivity.
- 13 March 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (6) , 725-745
3,5-Disubstituted pyrazoline as a promising core for anticancer agents: mechanisms of action and therapeutic potentials
The rapidly growing interest in the literature about the anticancer activity of 3,5-disubstituted pyrazolines and their promising therapeutic potentials/pharmacological properties, supported by the number of pyrazoline derivatives currently in clinical use or clinical trials, encouraged us to review the in vitro antiproliferative effects and biochemical investigations of probable mechanisms of action. Nevertheless, many reported pyrazoline-bearing compounds have anticancer activity without an explored mode of action, which opens new research avenues to examine their biochemical profiles further. Therefore, 3,5-disubstituted pyrazoline is a promising core that can be used to design new derivatives with anticancer activity based on the structure-activity relationship summarized in this review to obtain higher potency and selectivity.
- Open Access
- 29 October 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (47) , 34537-34555
Discovery of pyrazole-based analogs as CDK2 inhibitors with apoptotic-inducing activity: design, synthesis and molecular dynamics study
The discovery of novel CDK2 inhibitors is crucial for developing targeted anticancer therapies. Thus, in this study, we aimed to design, synthesize, and evaluate a series of novel pyrazole derivatives (2a–g, 7a–d, 8a and b, 9, and 10) for their potential as CDK2/cyclin A2 enzyme inhibitors. The newly synthesized compounds were screened in vitro at 50 μM for CDK2 inhibition, followed by IC50 profiling of the most promising candidates. Compounds 4, 7a, 7d, and 9 exhibited the strongest inhibition, with IC50 values of 3.82, 2.0, 1.47, and 0.96 μM, respectively. To assess their anti-proliferative effects, all target compounds were further screened against a panel of 60 National Cancer Institute (NCI) cell lines representing various carcinoma types. Among them, compound 4 demonstrated exceptional anti-proliferative activity with a mean growth inhibition (GI) of 96.47% across the panel, while compound 9 showed a mean GI of 65.90%. Additionally, compounds 2b and 7c exhibited notable inhibition against MCF7 breast cancer cells, with GI rates of 86.1% and 79.41%, respectively. Compound 4 was selected for further five-dose concentration evaluations, displaying a full-panel GI50 value of 3.81 μM, with a subpanel range of 2.36–9.17 μM. Western blot analysis of compounds 4 and 9 in HCT-116 cell lines confirmed their inhibitory effects on CDK2. Furthermore, compound 4 induced significant cell cycle arrest at the G1 phase and promoted apoptosis. In silico molecular docking studies revealed that compounds 4, 7a, 7d, and 9 adopt a similar binding mode as AT7519 (I) within the CDK2 binding site. Molecular dynamics simulations further validated the stability of these compounds within the catalytic domain of CDK2. ADME/TOPKAT analyses indicated their favorable pharmacokinetic profiles, which were confirmed by their low toxicity in normal cell lines. Based on these findings, it was concluded that the synthesized pyrazole derivatives, particularly compound 4, show potent CDK2 inhibition and significant anticancer activity, with promising drug-like properties and minimal toxicity. This positions them as strong candidates for further development as CDK2-targeting anticancer agents.
- 29 October 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (47) , 34537-34555
Open AccessDiscovery of pyrazole-based analogs as CDK2 inhibitors with apoptotic-inducing activity: design, synthesis and molecular dynamics study
The discovery of novel CDK2 inhibitors is crucial for developing targeted anticancer therapies. Thus, in this study, we aimed to design, synthesize, and evaluate a series of novel pyrazole derivatives (2a–g, 7a–d, 8a and b, 9, and 10) for their potential as CDK2/cyclin A2 enzyme inhibitors. The newly synthesized compounds were screened in vitro at 50 μM for CDK2 inhibition, followed by IC50 profiling of the most promising candidates. Compounds 4, 7a, 7d, and 9 exhibited the strongest inhibition, with IC50 values of 3.82, 2.0, 1.47, and 0.96 μM, respectively. To assess their anti-proliferative effects, all target compounds were further screened against a panel of 60 National Cancer Institute (NCI) cell lines representing various carcinoma types. Among them, compound 4 demonstrated exceptional anti-proliferative activity with a mean growth inhibition (GI) of 96.47% across the panel, while compound 9 showed a mean GI of 65.90%. Additionally, compounds 2b and 7c exhibited notable inhibition against MCF7 breast cancer cells, with GI rates of 86.1% and 79.41%, respectively. Compound 4 was selected for further five-dose concentration evaluations, displaying a full-panel GI50 value of 3.81 μM, with a subpanel range of 2.36–9.17 μM. Western blot analysis of compounds 4 and 9 in HCT-116 cell lines confirmed their inhibitory effects on CDK2. Furthermore, compound 4 induced significant cell cycle arrest at the G1 phase and promoted apoptosis. In silico molecular docking studies revealed that compounds 4, 7a, 7d, and 9 adopt a similar binding mode as AT7519 (I) within the CDK2 binding site. Molecular dynamics simulations further validated the stability of these compounds within the catalytic domain of CDK2. ADME/TOPKAT analyses indicated their favorable pharmacokinetic profiles, which were confirmed by their low toxicity in normal cell lines. Based on these findings, it was concluded that the synthesized pyrazole derivatives, particularly compound 4, show potent CDK2 inhibition and significant anticancer activity, with promising drug-like properties and minimal toxicity. This positions them as strong candidates for further development as CDK2-targeting anticancer agents.
- 6 August 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (16) , 1685-1703
An overview of pyridazin-3(2 H )-one: a core for developing bioactive agents targeting cardiovascular diseases and cancer
Cardiovascular diseases (CVDs) and cancer are the top two leading causes of death globally. Vasodilators are commonly used to treat various CVDs. In cancer treatment, targeted anticancer agents have been developed to minimize side effects compared with traditional chemotherapy. Many hypertension patients are more prone to cancer, a case known as reverse cardio-oncology. This leads to the search for drugs with dual activity or repurposing strategy to discover new therapeutic uses for known drugs. Recently, medicinal chemists have shown great interest in synthesizing pyridazinone derivatives due to their significant biological activities in tackling these critical health challenges. This review will concentrate on pyridazin-3(2H)-one-containing compounds as vasodilators and anticancer agents, along with a brief overview of various methods for their synthesis.
- 6 August 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (16) , 1685-1703
An overview of pyridazin-3(2 H )-one: a core for developing bioactive agents targeting cardiovascular diseases and cancer
Cardiovascular diseases (CVDs) and cancer are the top two leading causes of death globally. Vasodilators are commonly used to treat various CVDs. In cancer treatment, targeted anticancer agents have been developed to minimize side effects compared with traditional chemotherapy. Many hypertension patients are more prone to cancer, a case known as reverse cardio-oncology. This leads to the search for drugs with dual activity or repurposing strategy to discover new therapeutic uses for known drugs. Recently, medicinal chemists have shown great interest in synthesizing pyridazinone derivatives due to their significant biological activities in tackling these critical health challenges. This review will concentrate on pyridazin-3(2H)-one-containing compounds as vasodilators and anticancer agents, along with a brief overview of various methods for their synthesis.
- 19 April 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (10) , 963-981
Exploring of novel oxazolones and imidazolones as anti-inflammatory and analgesic candidates with cyclooxygenase inhibitory action
- 19 April 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (10) , 963-981
Exploring of novel oxazolones and imidazolones as anti-inflammatory and analgesic candidates with cyclooxygenase inhibitory action
- 16 February 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 145, 107213
Design, synthesis, and biological evaluation of some new 2-phenyl-3,6-pyridazinedione derivatives as PDE-5 inhibitors
- 16 February 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 145, 107213
Design, synthesis, and biological evaluation of some new 2-phenyl-3,6-pyridazinedione derivatives as PDE-5 inhibitors
- 30 January 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (4) , 349-368
Investigations of New N 1 -Substituted Pyrazoles as Anti-Inflammatory and Analgesic Agents having COX Inhibitory Activity
Background: The search is ongoing for ideal anti-inflammatory and analgesic agents with promising potency and reasonable selectivity. Methods: New N1-substituted pyrazoles with or without an acetam... Graphical abstract
- 30 January 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (4) , 349-368
Investigations of New N 1 -Substituted Pyrazoles as Anti-Inflammatory and Analgesic Agents having COX Inhibitory Activity
Background: The search is ongoing for ideal anti-inflammatory and analgesic agents with promising potency and reasonable selectivity. Methods: New N1-substituted pyrazoles with or without an acetam... Graphical abstract
- 21 March 2023
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 14 (5) , 899-920
Insights into targeting SARS-CoV-2: design, synthesis,in silicostudies and antiviral evaluation of new dimethylxanthine derivatives
The expanded structure- and ligand-based drug design strategy was utilized to obtain a multitargeting SARS-CoV-2 inhibitor, compound 9a, with an IC50value of 8.86 μM.
- 21 March 2023
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 14 (5) , 899-920
Insights into targeting SARS-CoV-2: design, synthesis,in silicostudies and antiviral evaluation of new dimethylxanthine derivatives
The expanded structure- and ligand-based drug design strategy was utilized to obtain a multitargeting SARS-CoV-2 inhibitor, compound 9a, with an IC50value of 8.86 μM.